Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 66 articles: HTML format

Single Articles

June 2025
1. DE GROOT AF, Cohen D, Heijns JB, Mandigers CMPW, et al
   Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01).
   Clin Cancer Res. 2025 Jun 10. doi: 10.1158/1078-0432.CCR-24-3402.
   PubMed     Abstract available
   
   
   May 2025
2. PRIEDIGKEIT N, Harrison B, Shue R, Hughes ME, et al
   Clinicogenomic characterization of inflammatory breast cancer.
   Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-24-2081.
   PubMed     Abstract available
   
   
   
3. LI Y, Zhang T, Korkaya H, Liu S, et al
   Correction: Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells.
   Clin Cancer Res. 2025;31:2062.
   PubMed    
   
   
   
4. GWIN WR 3RD, Hurvitz SA
   TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs.
   Clin Cancer Res. 2025;31:1824-1826.
   PubMed     Abstract available
   
   
   
5. CHUMSRI S, Larson JJ, Liu E, Tenner KS, et al
   Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer.
   Clin Cancer Res. 2025;31:1885-1893.
   PubMed     Abstract available
   
   
   
6. FASCHING PA, Schmatloch S, Hauke J, Rey J, et al
   Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.
   Clin Cancer Res. 2025;31:1596-1604.
   PubMed     Abstract available
   
   
   April 2025
7. CLARK AS, Zhao F, Klein P, Montero AJ, et al
   A Phase II Randomized Study of Paclitaxel alone or combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor Positive Breast Cancer: the BRACELET-01/PrE0113 study.
   Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-2701.
   PubMed     Abstract available
   
   
   
8. JOHANSSON H, Macis D, Oliva M, Puntoni M, et al
   Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial.
   Clin Cancer Res. 2025 Apr 28:OF1-OF6. doi: 10.1158/1078-0432.CCR-24-2987.
   PubMed     Abstract available
   
   
   
9. JIAO D, Qiao J, Sun X, Wang C, et al
   Application of Neoadjuvant Docetaxel Plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.
   Clin Cancer Res. 2025 Apr 21. doi: 10.1158/1078-0432.CCR-25-0289.
   PubMed     Abstract available
   
   
   
10. YAP TA, Goldman JW, Vinayak S, Tomova A, et al
    First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.
    Clin Cancer Res. 2025 Apr 17. doi: 10.1158/1078-0432.CCR-24-2740.
    PubMed     Abstract available
    
    
    
11. GOUGH M, Kwah KKX, Khan T, Ghosh S, et al
    Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers.
    Clin Cancer Res. 2025;31:1504-1519.
    PubMed     Abstract available
    
    
    
12. JONES LW, Lavery JA, Tsai BL, Moskowitz CS, et al
    A Co-Clinical Trial of Exercise Therapy in Breast Cancer Prevention.
    Clin Cancer Res. 2025 Apr 4. doi: 10.1158/1078-0432.CCR-24-4298.
    PubMed     Abstract available
    
    
    
13. LIU J, Song C, Yang Y, Wang X, et al
    Safety and Efficacy of KN046 in combination with KN026 in Patients with advanced HER2-positive Breast Cancer: a Phase II Trial.
    Clin Cancer Res. 2025 Apr 4. doi: 10.1158/1078-0432.CCR-24-3888.
    PubMed     Abstract available
    
    
    March 2025
14. JILDERDA MF, Zhang Y, Rebattu V, Salunga R, et al
    Identification of Early-Stage Breast Cancer with Minimal Risk of Recurrence by Breast Cancer Index.
    Clin Cancer Res. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-3836.
    PubMed     Abstract available
    
    
    
15. ADEMUYIWA FO, Ma CX, Weilbaecher K, Suresh R, et al
    Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer.
    Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3145.
    PubMed     Abstract available
    
    
    
16. JANNI W, Friedl TWP, Yab TC, Bidard FC, et al
    Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis.
    Clin Cancer Res. 2025 Mar 18. doi: 10.1158/1078-0432.CCR-24-3108.
    PubMed     Abstract available
    
    
    February 2025
17. FASCHING PA, Slamon D, Nowecki Z, Kukielka-Budny B, et al
    Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial.
    Clin Cancer Res. 2025 Feb 28. doi: 10.1158/1078-0432.CCR-24-1724.
    PubMed     Abstract available
    
    
    
18. LIN CA, Chica-Parrado MR, Unni N, Jaeger E, et al
    ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer.
    Clin Cancer Res. 2025 Feb 25. doi: 10.1158/1078-0432.CCR-24-2307.
    PubMed     Abstract available
    
    
    
19. POUGOUE KETCHEMEN J, Njotu FN, Babeker H, Monzer A, et al
    Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.
    Clin Cancer Res. 2025;31:685-696.
    PubMed     Abstract available
    
    
    
20. GOEL S, Jovanovic B, Chu X, Hughes M, et al
    A phase II study of abemaciclib for patients with retinoblastoma-positive, triple-negative metastatic breast cancer.
    Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2647.
    PubMed     Abstract available
    
    
    
21. DRAKE RJG, Landen AH, Holmberg E, Stenmark Tullberg A, et al
    Endothelial cell pY397-FAK expression predicts risk of breast cancer recurrences after radiotherapy in SweBCG91-RT cohort.
    Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2939.
    PubMed     Abstract available
    
    
    
22. KOBOLD S
    RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
    Clin Cancer Res. 2025;31:437-438.
    PubMed     Abstract available
    
    
    
23. JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al
    Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.
    Clin Cancer Res. 2025;31:503-514.
    PubMed     Abstract available
    
    
    January 2025
24. SOOD R, Niemierko A, Ryan L, Spring L, et al
    Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jan 27. doi: 10.1158/1078-0432.CCR-24-2825.
    PubMed     Abstract available
    
    
    
25. GOUDA MA, Gonugunta A, Dumbrava EE, Yap TA, et al
    Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jan 22. doi: 10.1158/1078-0432.CCR-24-3468.
    PubMed     Abstract available
    
    
    
26. RIOS-HOYO A, Xiong K, Dai J, Yau C, et al
    Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
    Clin Cancer Res. 2025;31:403-413.
    PubMed     Abstract available
    
    
    
27. VIDAL M, Falato C, Pascual T, Sanchez-Bayona R, et al
    Elacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: results from the preoperative window-of-opportunity ELIPSE trial.
    Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-2460.
    PubMed     Abstract available
    
    
    
28. ELLIOTT MJ, Howarth K, Main S, Fuentes Antras J, et al
    Ultrasensitive Detection and Monitoring of Circulating Tumor DNA using Structural Variants in Early-Stage Breast Cancer.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-3472.
    PubMed     Abstract available
    
    
    
29. MAURYA SK, Jaramillo-Gomez JA, Rehman AU, Gautam SK, et al
    Mucin5AC promotes breast cancer brain metastasis through cMET/CD44v6.
    Clin Cancer Res. 2025 Jan 6. doi: 10.1158/1078-0432.CCR-24-1977.
    PubMed     Abstract available
    
    
    
30. HUANG H, Couch RE, Karam R, Hu C, et al
    Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.
    Clin Cancer Res. 2025;31:130-138.
    PubMed     Abstract available
    
    
    
31. ABELMAN RO, Wu B, Barnes H, Medford A, et al
    TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-2771.
    PubMed     Abstract available
    
    
    December 2024
32. VILLACAMPA G, Llop-Guevara A, Filmann N, Herencia A, et al
    RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-3148.
    PubMed     Abstract available
    
    
    
33. HAMILTON E, Galsky MD, Ochsenreither S, Del Conte G, et al
    Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
    Clin Cancer Res. 2024;30:5548-5558.
    PubMed     Abstract available
    
    
    November 2024
34. MERIC-BERNSTAM F, Yuca E, Evans KW, Zhao M, et al
    Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models.
    Clin Cancer Res. 2024 Nov 25. doi: 10.1158/1078-0432.CCR-24-1948.
    PubMed     Abstract available
    
    
    
35. FERRARIO C, Mackey J, Gelmon KA, Levasseur N, et al
    Phase Ib pharmacodynamic study of the MNK inhibitor Tomivosertib (eFT508) combined with paclitaxel in patients with refractory metastatic breast cancer.
    Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-0841.
    PubMed     Abstract available
    
    
    
36. ANAMPA JD, Flynn DL, Leary C, Oh S, et al
    Phase Ib clinical and pharmacodynamic study of the TIE2 kinase inhibitor rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer.
    Clin Cancer Res. 2024 Nov 12. doi: 10.1158/1078-0432.CCR-24-2464.
    PubMed     Abstract available
    
    
    October 2024
37. REDITI M, Fimereli D, Mileva M, Wimana Z, et al
    Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial.
    Clin Cancer Res. 2024 Oct 29. doi: 10.1158/1078-0432.CCR-24-1007.
    PubMed     Abstract available
    
    
    
38. NEVEN P, Stahl N, Vidal M, Martin M, et al
    A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study.
    Clin Cancer Res. 2024 Oct 8. doi: 10.1158/1078-0432.CCR-24-2113.
    PubMed     Abstract available
    
    
    
39. BARDIA A, Cortes J, Bidard FC, Neven P, et al
    Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
    Clin Cancer Res. 2024;30:4299-4309.
    PubMed     Abstract available
    
    
    September 2024
40. DUGO M, Huang CS, Egle D, Bermejo B, et al
    The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2024 Sep 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0149.
    PubMed     Abstract available
    
    
    
41. QUINTELA-FANDINO M, Bermejo B, Zamora E, Moreno F, et al
    High mechanical conditioning by tumor extracellular matrix stiffness is a predictive biomarker for anti-fibrotic therapy in HER2-negative breast cancer.
    Clin Cancer Res. 2024 Sep 16. doi: 10.1158/1078-0432.CCR-24-1518.
    PubMed     Abstract available
    
    
    
42. GIORDANO A, Kumthekar PU, Jin Q, Binboga Kurt B, et al
    A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer.
    Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1161.
    PubMed     Abstract available
    
    
    August 2024
43. ROJO F, Najera L, Lirola J, Jimenez J, et al
    Editor's Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis.
    Clin Cancer Res. 2024;30:3641.
    PubMed    
    
    
    
44. GILLMORE R, Xue SA, Holler A, Kaeda J, et al
    Editor's Note: Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer.
    Clin Cancer Res. 2024;30:3642.
    PubMed    
    
    
    
45. JOVANOVIC B, Church SE, Gorman KM, North K, et al
    Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies.
    Clin Cancer Res. 2024 Aug 13. doi: 10.1158/1078-0432.CCR-23-1242.
    PubMed     Abstract available
    
    
    
46. PIFFOUX M, Jacquemin J, Petera M, Durand S, et al
    Metabolomic prediction of breast cancer treatment induced neurological and metabolic toxicities.
    Clin Cancer Res. 2024 Aug 6. doi: 10.1158/1078-0432.CCR-24-0195.
    PubMed     Abstract available
    
    
    July 2024
47. DENT RA, Kim SB, Oliveira M, Barrios C, et al
    Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
    Clin Cancer Res. 2024 Jul 26. doi: 10.1158/1078-0432.CCR-24-0465.
    PubMed     Abstract available
    
    
    
48. SUN X, Kennedy LC, Gonzalez-Ericsson PI, Sanchez V, et al
    Associations of immune checkpoint predictive biomarkers MHC-I and MHC-II with clinical and molecular features in a diverse breast cancer cohort.
    Clin Cancer Res. 2024 Jul 15. doi: 10.1158/1078-0432.CCR-24-1286.
    PubMed     Abstract available
    
    
    
49. LLOMBART-CUSSAC A, Perez-Garcia J, Braso-Maristany F, Pare L, et al
    HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial.
    Clin Cancer Res. 2024 Jul 12. doi: 10.1158/1078-0432.CCR-24-0464.
    PubMed     Abstract available
    
    
    
50. STEARNS V, Jegede OA, Chang VT, Skaar TC, et al
    A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
    Clin Cancer Res. 2024;30:2709-2718.
    PubMed     Abstract available
    
    
    June 2024
51. SCHMIESTER L, Braso-Maristany F, Gonzalez-Farre B, Pascual T, et al
    Computational model predicts patient outcomes in Luminal B breast cancer treated with endocrine therapy and CDK4/6 inhibition.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-24-0244.
    PubMed     Abstract available
    
    
    
52. JANK P, Karn T, van Mackelenbergh M, Lindner J, et al
    An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0459.
    PubMed     Abstract available
    
    
    
53. ZHANG Q, Cai Z, Gerratana L, Davis AA, et al
    Early evaluation of risk stratification and clinical outcomes for patients with advanced breast cancer through combined monitoring of baseline circulating tumor cells and DNA.
    Clin Cancer Res. 2024 Jun 3. doi: 10.1158/1078-0432.CCR-24-0535.
    PubMed     Abstract available
    
    
    
54. MAKHLIN I, Demissei BG, D'Agostino R, Hundley WG, et al
    Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.
    Clin Cancer Res. 2024;30:2370-2376.
    PubMed     Abstract available
    
    
    May 2024
55. GOUGH SM, Flanagan JJ, Teh J, Andreoli M, et al
    Oral estrogen receptor PROTAC(R) vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models.
    Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-23-3465.
    PubMed     Abstract available
    
    
    
56. CHEUNG A, Chenoweth AM, Johansson A, Laddach R, et al
    Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth.
    Clin Cancer Res. 2024 May 21. doi: 10.1158/1078-0432.CCR-23-3110.
    PubMed     Abstract available
    
    
    
57. HADDAD TC, Suman VJ, Giridhar KV, Sideras K, et al
    Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial.
    Clin Cancer Res. 2024 May 16. doi: 10.1158/1078-0432.CCR-24-0341.
    PubMed     Abstract available
    
    
    
58. WANDER SA, Bardia A
    Cracking the Genomic Code of CDK4/6 Inhibitor Resistance.
    Clin Cancer Res. 2024;30:2008-2010.
    PubMed     Abstract available
    
    
    
59. BARDIA A, Sun S, Thimmiah N, Coates JT, et al
    Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients.
    Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-24-0428.
    PubMed     Abstract available
    
    
    April 2024
60. BOTTOSSO M, Miglietta F, Vernaci GM, Giarratano T, et al
    Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer.
    Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020.
    PubMed     Abstract available
    
    
    
61. IWASE T, Cohen EN, Gao H, Alexander A, et al
    Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2947.
    PubMed     Abstract available
    
    
    
62. MOYER CL, Lanier A, Qian J, Coleman D, et al
    IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy.
    Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-23-3839.
    PubMed     Abstract available
    
    
    
63. HAN YJ, Liu S, Hardeman A, Rajagopal PS, et al
    The VEGF-Hypoxia Signature is Upregulated in Basal like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer.
    Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-1526.
    PubMed     Abstract available
    
    
    
64. CONNOLLY RM, Wang V, Hyman DM, Grivas P, et al
    Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
    Clin Cancer Res. 2024;30:1273-1280.
    PubMed     Abstract available
    
    
    March 2024
65. MAGBANUA MJM, Ahmed Z, Sayaman RW, Brown Swigart L, et al
    Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-23-2928.
    PubMed     Abstract available
    
    
    
66. MARTIN M, Yoder R, Salgado R, Del Monte-Millan M, et al
    Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-24-0106.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.